{"id":"r2-lenalidomide-ixazomib-maintenance","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Lenalidomide is an immunomodulatory drug (IMiD) that enhances T-cell proliferation, NK cell activation, and TNF-α production while inhibiting angiogenesis. Ixazomib is a proteasome inhibitor that blocks NF-κB signaling and induces apoptosis in myeloma cells. Together in maintenance therapy, they provide dual mechanisms to prevent relapse and prolong progression-free survival in multiple myeloma patients.","oneSentence":"Lenalidomide and ixazomib work together as immunomodulatory and proteasome inhibitor agents to enhance anti-myeloma immune responses and suppress tumor cell proliferation in multiple myeloma maintenance therapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:18.514Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma maintenance therapy (post-induction treatment)"}]},"trialDetails":[{"nctId":"NCT03720041","phase":"PHASE3","title":"Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2020-08-04","conditions":"Multiple Myeloma","enrollment":740}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Revlimid","Ninlaro"],"phase":"phase_3","status":"active","brandName":"R2: Lenalidomide + ixazomib maintenance","genericName":"R2: Lenalidomide + ixazomib maintenance","companyName":"University of Leeds","companyId":"university-of-leeds","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenalidomide and ixazomib work together as immunomodulatory and proteasome inhibitor agents to enhance anti-myeloma immune responses and suppress tumor cell proliferation in multiple myeloma maintenance therapy. Used for Multiple myeloma maintenance therapy (post-induction treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}